MW-150

Research use only, not for human use.

MW-150 (MW01-18-150 SRM) is a novel potent, selective, CNS penetrant and orally active inhibitor of p38α MAPK with Ki of 101 nM.

MW-150 (MW01-18-150 SRM) is a novel potent, selective, CNS penetrant and orally active inhibitor of p38α MAPK with Ki of 101 nM; effectively suppresses hippocampal-dependent associative and spatial memory deficits in synaptic dysfunction mouse models; also can selectively modulate neuroinflammatory responses associated with pathology progression.

MW-150 inhibits in a concentration-dependent manner the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia. MW-150 blocks in a concentration-dependent manner the increased IL-1β production by activated glia. The IC50 values are 332 nM and 936 nM for MK2 and IL-1β, respectively.

MW-150 (2.5 mg/kg; oral daily for 3-4 months) improves the APP/PS1 transgenic (Tg) mice performance in radial arm water maze (RAWM) and contextual fear conditioning tests.MW-150 (2.5 mg/kg; given i.p.; daily for 14 days) treatment in APPNLh/NLh × PSP264L/P264L knock-in mouse (with no overexpression of the amyloid precursor protein) exhibits RAWM behavior indistinguishable from WT mice. Animal Model:APP/PS1 transgenic (Tg) mouse (overexpresses amyloid-beta)Dosage:2.5 mg/kg Administration:Oral daily; 3-4 months (until cognitive impairment is present) Result:Improved the Tg mice performance in radial arm water maze (RAWM) and contextual fear conditioning tests.

MW01-18-150SRM | MW 150 | MW150

MAPK/ERK Signaling

p38 MAPK

p38 MAPK

——

——

1628502-91-9

381.483

C24H23N5

>98% (HPLC)

In Vitro:?DMSO : 40 mg/mL (104.86 mM)

CN1CCN(CC1)C2=NN=C(C(=C2)C3=CC=NC=C3)C4=CC5=CC=CC=C5C=C4

6-(4-methylpiperazin-1-yl)-3-(naphthalen-2-yl)-4-(pyridin-4-yl)pyridazine

(-20℃)

With Ice Pack

≥ 2 years